Global Kidney Cancer Drugs Market Research Report 2023: Forecasts to 2027 & 2032 with Focus on Axitinib (Inlyta), Cabozantinib (cabometyx), and Pazopanib
13 mars 2023 08h53 HE
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global kidney cancer drugs market will...
Global Kidney Cancer Drugs Market Report 2022-2026 & 2030 - Focus on Immunotherapy, Chemotherapy and Targeted Therapy
19 avr. 2022 04h48 HE
|
Research and Markets
Dublin, April 19, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2022, Type, Product, End Users" report has been added to ResearchAndMarkets.com's offering. The global...
Kidney Cancer Drugs Industry Assessment and Recovery to 2030 - Insights on Drugs, Trends, Global Market Shares, Competitors, Strategies and More
04 févr. 2022 04h38 HE
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering. The...
Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting
01 nov. 2021 07h30 HE
|
Graybug Vision, Inc.
BALTIMORE, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Global Kidney Cancer Diagnostics and Therapeutics Market (2020 to 2026) - Featuring Abbvie, Active Biotech and AstraZeneca Among Others
05 août 2021 07h53 HE
|
Research and Markets
Dublin, Aug. 05, 2021 (GLOBE NEWSWIRE) -- The "Global Kidney Cancer Diagnostics and Therapeutics Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global kidney...
Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial
09 mars 2021 07h30 HE
|
Graybug Vision, Inc.
Median time to first supportive therapy was 5 months for GB-102 1mg48% of patients in the GB-102 1 mg arm were rescue-free for at least 6 monthsControl of retinal thickness was consistent across all...
Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments
04 mars 2021 17h04 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the...
Graybug Vision to Participate in SVB Leerink Global Healthcare Conference
17 févr. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team
01 févr. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...
Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021
07 janv. 2021 07h30 HE
|
Graybug Vision, Inc.
REDWOOD CITY, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines to treat...